Gemstone Biotherapeutics Adds New Board Member
Baltimore, Maryland (PRWEB) September 01, 2015 -- Gemstone Biotherapeutics LLC (Gemstone Bio), a Baltimore-based biotechnology company and pioneer in the field of regenerative medicine, announced the appointment of Geoff MacKay to Gemstone Bio’s Board of Directors.
MacKay, an accomplished and visionary leader in the pharma, biotech, and device industries, brings over 25 years of diverse senior executive experience driving growth within global companies. His experience includes senior leadership roles at Novartis, where he helped guide global R&D and commercial strategies for various therapeutics and at Organogenesis Inc., where as President and CEO he built the company into a world-renowned cell therapy business.
“Geoff brings a deep understanding of the regenerative medicine and wound healing industries, a background in strategy and operations, and a demonstrated record of accomplishment in bringing innovative technologies to market. His background and knowledge will be very beneficial as we take Gemstone Bio to the next level,” said George Davis, CEO of Gemstone Bio. “The company is in a strong position as a result of our latest round of investment and the superior study results released last month. With the addition of Geoff to our board, we continue to add depth and capability to our team.”
“I am delighted to join the Gemstone Bio Board of Directors and have the opportunity to work with the team that is revolutionizing the wound care industry. I look forward to sharing my experience with the team and contributing to the growth of the company,” said MacKay.
Mr. MacKay graduated from McGill University with a Bachelor’s degree in Psychology and also earned a Certificate in Marketing Management. He served as Chairman for the Alliance for Regenerative Medicine (ARM) and remains an active participant.
ABOUT GEMSTONE BIOTHERAPEUTICS
Gemstone Biotherapeutics LLC (Gemstone Bio), an award-winning biotechnology company based in Baltimore, is pioneering the field of regenerative medicine. The company’s core technologies utilize cell engineering methods and biomaterials to promote vascularization, a critical component in advanced tissue repair and regeneration. Gemstone is developing these technologies, originally created in laboratories within the Department of Chemical and Biomolecular Engineering at Johns Hopkins University, for advanced therapeutic applications in wound care and other chronic diseases. For more information, visit http://www.gemstonebio.com.
Adrienne Peres for Gemstone Biotherapeutics, Abel Communications, http://www.abelcommunications.com/, +1 (443) 869-2197 Ext: 146, [email protected]
Share this article